By incorporating a gene-suppressing drug into an over-the-counter gel, researchers at Albert Einstein College of Medicine and their colleagues cut healing time by half and significantly improved healing outcomes compared to control treatments.
Results from the combination therapy, which was tested in mice, were published online today in Advances in Wound Care,
“Not only did wound healing occur more rapidly and completely, but actual regeneration occurred, with hair follicles and the skin’s supportive collagen network restored in wounded skin—clinically important improvements that are unprecedented in wound care,” says senior author David J. Sharp, Ph.D., professor of physiology & biophysics at Einstein. “We foresee this therapy having broad application for all sorts of wounds, from playground cuts to battlefield injuries to chronic wounds.”
Chronic wounds alone affect 6.5 million Americans and cost $25 billion in annual healthcare costs. Over the past several decades, few advances have been made in treating wounds of any type.
In 2015, Dr. Sharp and colleagues discovered that an enzyme called fidgetin-like 2 (FL2) puts the brakes on skin cells as they migrate towards wounds to heal them. He reasoned that reducing FL2 levels might enable healing cells to reach their destination faster. So he and his colleagues developed small interfering RNA molecules (siRNAs) that specifically inhibit the gene that codes for FL2. When the siRNAs were encased in nanoparticles and sprayed on skin wounds in mice, the treated wounds healed faster than untreated wounds.
In the current study, Dr. Sharp enhanced the siRNAs’ wound-healing potential by combining them with PluroGel—a protective gel that keeps wounds moist and has antimicrobial properties when applied to bandages and other wound dressings. In addition, Dr. Sharp incorporated the siRNAs into microparticles made of collagen, a naturally occurring protein that readily releases its siRNA “cargo” after coming in contact with the skin.
The FL2-siRNA/PluroGel combination was applied to mice with either skin excisions or burns. For comparison, studies involving both types of skin injuries also used two control groups: mice treated with PluroGel alone and mice treated with PluroGel plus siRNA that did not target the gene for FL2. Wounds were treated on the day of the skin excision or burn and again two, four and six days later. For 14 days following the injuries, wounds were assessed by investigators who were “blinded” as to the treatment the mice received.
On the fourth day after mice treated for excision wounds, the open wound areas of mice in the two control groups were nearly twice as large as the wound areas in mice treated with the FL2-siRNA/PluroGel combination. Several mice treated with the combination therapy also had hair follicles present in the wound zone, while no such structures were seen in the control mice.
For mice treated for burns: by 14-days post injury, the wounds of mice in both control groups were more than one-third larger than in the mice treated with the FL2-siRNA/PluroGel combination. In addition, the burn wounds of all mice treated with the FL2-siRNA/PluroGel combination had closed completely by day 14; by comparison, 25 percent and 30 percent of treated wounds in the PluroGel and PluroGel/nontarget siRNA control groups, respectively, remained unhealed at that time.
“These results show that FL2-siRNA plus PluroGel is a highly promising wound treatment,” says Adam Kramer, a Ph.D. candidate in Dr. Sharp’s lab and co-lead author. “By lowering FL2 levels in skin cells, the FL2-siRNA helps cells reach wound sites much faster than they ordinarily would—essential for minimizing scarring and preventing wounds from becoming chronic. And by hydrating wounds and inhibiting microbes, PluroGel offers important additional wound-healing benefits.”
Dr. Sharp and Brian O’Rourke, Ph.D., the paper’s co-lead author and chief scientist at MicroCures, Inc., have achieved similar success in treating skin wounds in pigs—animals with skin that closely resembles human skin. Dr. Sharp’s team plans to seek permission from the U.S. Food and Drug Administration to test their wound-healing therapy in clinical trials.
Learn more: Novel Combination Therapy Promotes Wound Healing
The Latest on: Combination therapy
via Google News
The Latest on: Combination therapy
- Phase 2 CALIBRATE Study Indicates Benlysta as Additional Therapy for Lupus Nephritis is Safeon August 10, 2020 at 11:39 am
A new phase 2 study shows Benlysta is safe in people with lupus nephritis when used in combination with other therapies.
- Danadams to increase ARV portfolio from monotherapy to combination therapyon August 8, 2020 at 8:13 am
Department of the Danadams Pharmaceuticals Industry Limited has said it is working to increase the Antiretroviral drug’s portfolio from monotherapy to combination therapy.
- Opdivo-Yervoy Combination Shows Promise in Certain Patients with Previously Treated RCCon August 6, 2020 at 11:48 am
While the combination of Opdivo and Yervoy is one of several treatment options for patients with metastatic renal cell carcinoma, many patients will likely progress after initial treatment. However, ...
- Autism Symptoms Improve with Innovative Combination Therapyon August 4, 2020 at 6:08 am
OVERLAND PARK, Kan., Aug. 4, 2020 /PR Newswire/ -- Nemechek Technologies, LLC announced publication of a peer-reviewed article in Applied Psychology titled, "Autism Spectrum Disorder Symptoms Improve ...
- PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology (SLBio) to evaluate a combination therapy to treat NSCLCon August 3, 2020 at 6:16 am
PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a research collaboration with Wuxi Shuangliang Biotechnology (SLBio) to evaluate the combination of each party's clinical candidate, olinvacimab and ...
- FDA Approves Combination Therapy for Treating Advanced Melanomaon July 30, 2020 at 4:09 pm
The therapy is currently utilized for treatment of patients with certain types of cancer, including urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, and hepatocellular ...
- Combination Therapy Quells COVID-19 Cytokine Stormon July 23, 2020 at 5:00 pm
They compared them with another 86 patients with COVID-19 treated with supportive care before initiation of the combination therapy protocol. Participants with CSS had an oxygen saturation of 94% ...
- Global Artemisinin Combination Therapy Market 2020: Latest In-Depth Report Segment by Manufacturers, Type, Applications and Dynamicson July 23, 2020 at 4:19 am
Jul 23, 2020 (Profound via COMTEX) -- A recent report provides crucial insights along with application based and forecast information in the Global Artemisinin Combination Therapy Market.
- Potential Combination Therapy Discovered for Treating Head and Neck Squamous Cell Carcinomaon July 22, 2020 at 5:06 am
PD1 blockade-based combination therapy has been approved as a first-line treatment for HNSCC. However, the response rate remains relatively low, and patients with HNSCC eventually relapse.
via Bing News